The Motley Fool

2 unloved FTSE 100 stocks I’d buy before it’s too late

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

macro shot of computer monitor with FTSE 100 stock market data in trading application
Image source: Getty Images

As the UK moves out of lockdown and the economy’s wheels begin to turn a little quicker, the FTSE 100 has gained a boost and has tracked upwards quickly from the start of April. Good news for the broader economy, however, does not always equate to good news for individual companies.

I’ve pulled out two Footsie companies that have had a difficult time of late but, as a result, may represent an opportunity for me to buy. I will personally be following their progress closely to make the most of their lower cost before a potential rise.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!


The chances are that you’ve read quite a bit about AstraZeneca (LSE: AZN) in the news lately. The FTSE 100 company has had a bit of a rollercoaster ride of late, soaring as its Covid-19 vaccine began its rollout across Europe and now hitting a tricky spot as reports over potential blood clot risks of this vaccine arose.

It’s my view that the market has overreacted to the news because the vaccine represents only a relatively small part of its overall business. In fact, the crown jewel for AstraZeneca is its portfolio of oncology treatments that achieved sales of $11.4bn in 2020, with the three major treatments in that portfolio growing sales by over 35% year-on-year.

Currently, the company won’t take any profits from its vaccine until July of this year, after which there are estimates it will bring in $2bn in sales in 2022. Not a small sum but when its top selling oncology product, Tagrisso, is already bringing in $4.3bn and growing, it does put this in perspective.

With the negative PR likely to rumble on, shares in the company could continue their downward trend from highs of last year. This is definitely one I’ll be watching and potentially buying into should they drop even further.


Covid-19 has hit many businesses on the FTSE 100 hard, though many are recovering as the UK begins to open up. Some are recovering quicker than others, and one that still has some way to go before getting back to pre-pandemic levels is HSBC (LSE: HSBA). Prior to the pandemic, shares in the company were selling at just under 600p but have now fallen to around the 430p level.

This isn’t unusual in the banking sector, other companies are also fighting their way back to previous levels, but for HSBC the situation is a little different. Not only is it down on early 2020 figures, it’s also been on a decline since reaching highs of almost 800p in 2018.

Like other UK banks, there has been significant amount of restructuring taking place since the financial crisis of 2008, and current CEO, Noel Quinn, has previously announced plans to reduce the cost base of the business to increase earnings, as it deals with the current low interest rate environment.

One factor that could significantly boost earnings is the company’s performance in Asia, particularly China. HSBC has a strong presence in China and signalled back in February that it would pivot its focus towards Asia where it generates 90% of the company’s profit.

With some Asian countries, specifically China, faring much better during the pandemic and likewise seeing a rapid rate of recovery, this could see HSBC’s strategic position there pay off. This is why I’ll keep an eye on the company to see whether it can begin to outperform its FTSE 100 peers in the future, with a view to buying for the long term.

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to get access to our presentation, and learn how to get the name of this 'double agent'!

Ben Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.